Abstract
The discovery and supply of plant-derived anti-cancer compounds remain challenging given their low bioavailability and structural complexity. Reconstituting the pathways of these compounds in heterologous hosts is a promising solution; however, requires the complete elucidation of the biosynthetic genes involved and extensive metabolic engineering to optimise enzyme activity and metabolic flux. This review describes the current strategies and recent advancements in the production of these valuable therapeutic compounds, and highlights plant-derived immunomodulators as an emerging class of anti-cancer agents.
Cite
CITATION STYLE
Carqueijeiro, I., Langley, C., Grzech, D., Koudounas, K., Papon, N., O’Connor, S. E., & Courdavault, V. (2020, October 1). Beyond the semi-synthetic artemisinin: metabolic engineering of plant-derived anti-cancer drugs. Current Opinion in Biotechnology. Elsevier Ltd. https://doi.org/10.1016/j.copbio.2019.11.017
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
